Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial. Lundbeck’s acquisition of Pexton Pharma and its Parkinson’s disease candidate foliglurax has ended up being a bust, after the ... Lundbeck is already a big player in neurology and

Latest news

More from news
Approximately 112 fully matching, plus 399 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely.

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimers disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    That’s not dampening enthusiasm for the emerging field, however, and by some estimates, just about every big pharma company is active. ... C4 also has a collaboration in place with Biogen focusing on neurological conditions such as Alzheimer’s

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Research into treatments for Alzheimer’s has become disappointingly predictable, with trials and candidates in the area regularly abandoned following underwhelming results. ... It was just another in a string of late-stage failures in Alzheimer’s

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimers disease

    plaques and oligomers formed by beta-amyloid occur outside the brain cells of people with Alzheimer’s. ... Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present.

More from intelligence
Approximately 8 fully matching, plus 40 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • Digital therapeutics and their impact on society

    This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma.

  • Are we ready for an Alzheimer's disease modifying treatment

    Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. ... However, Alzheimer’s disease-modifying treatments (DMTs) have not progressed as much in the last 15 years as we all hoped.

  • Diagnosing the lag in neuropsychiatric treatments

    Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and schizophrenia can affect any part of the brain or nervous system function. ... It’s a highly selective and difficult to

  • 'Fake news': battling misinformation in healthcare

    An article published just three days later, again from ‘The Telegraph’ , plays on the  growing threat of Alzheimer’s. ... This means it can’t currently be stated that retinal changes had occurred before or after the participants Alzheimer’s

  • Havas Lynx shines a spotlight on carers

    Commenting on the white paper’s findings, Havas Lynx CEO, Dave Hunt, said:. ... References:. Alzheimer’s Disease International (2013) http://bit.ly/2nPw6QK (Accessed April 2017). Carers UK (2015)   (Accessed April 2017).

More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics